Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > New Press Release - Spectral Medical Provides January Tigris Trial Update

<< Previous

Bullboard Posts

Next >>

Comment by BlueJays9293on Jan 30, 2024 1:19pm

142 Views

Post# 35853020

RE:RE:New Press Release - Spectral Medical Provides January Tigris Trial Update

It takes 28 days from enrolling a patient to get their mortality rate so the effects of these 4 patients won't factor into "exceeding expectations" until February so I don't see this as a big deal since the January 10 update still had that phrase.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale